- Home
- URGN vs WRLD Comparison
URGN vs WRLD Comparison
Compare URGN & WRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- WRLD
- Stock Information
- Founded
- URGN 2004
- WRLD 1962
- Country
- URGN United States
- WRLD United States
- Employees
- URGN N/A
- WRLD N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- WRLD Finance: Consumer Services
- Sector
- URGN Health Care
- WRLD Finance
- Exchange
- URGN Nasdaq
- WRLD Nasdaq
- Market Cap
- URGN 830.4M
- WRLD 859.5M
- IPO Year
- URGN 2017
- WRLD 1991
- Fundamental
- Price
- URGN $16.82
- WRLD $167.79
- Analyst Decision
- URGN Strong Buy
- WRLD
- Analyst Count
- URGN 8
- WRLD 0
- Target Price
- URGN $28.50
- WRLD N/A
- AVG Volume (30 Days)
- URGN 1.2M
- WRLD 55.0K
- Earning Date
- URGN 11-05-2025
- WRLD 10-24-2025
- Dividend Yield
- URGN N/A
- WRLD N/A
- EPS Growth
- URGN N/A
- WRLD 10.95
- EPS
- URGN N/A
- WRLD 14.92
- Revenue
- URGN $94,238,000.00
- WRLD $567,706,032.00
- Revenue This Year
- URGN $39.63
- WRLD N/A
- Revenue Next Year
- URGN $111.49
- WRLD $3.55
- P/E Ratio
- URGN N/A
- WRLD $11.24
- Revenue Growth
- URGN 10.85
- WRLD 0.80
- 52 Week Low
- URGN $3.42
- WRLD $104.99
- 52 Week High
- URGN $21.71
- WRLD $185.48
- Technical
- Relative Strength Index (RSI)
- URGN 42.97
- WRLD 44.92
- Support Level
- URGN $15.86
- WRLD $174.59
- Resistance Level
- URGN $17.43
- WRLD $185.39
- Average True Range (ATR)
- URGN 1.06
- WRLD 6.20
- MACD
- URGN -0.15
- WRLD -0.93
- Stochastic Oscillator
- URGN 23.05
- WRLD 13.20
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About WRLD World Acceptance Corporation
World Acceptance Corp operates a small-loan consumer finance business. The company offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. It also offers income tax return preparation services to its loan customers and other individuals. The Company operates 1,024 branches in Alabama, Georgia, Idaho, Illinois, Indiana, Kentucky, Louisiana, Mississippi, Missouri, New Mexico, Oklahoma, South Carolina, Texas, Tennessee, Utah, and Wisconsin.